Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Encorafenib + Hydroxychloroquine + Panitumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Encorafenib||Braftovi||LGX818||BRAF Inhibitor 21||Braftovi (encorafenib) is an inhibitor of Raf kinase with selective activity against BRAF V600E, resulting in growth inhibition (PMID: 24864047). Braftovi (encorafenib) is FDA approved for use in combination with Mektovi (binimetinib) in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, and in combination with Erbitux (cetuximab) in patients with metastatic colorectal cancer with BRAF V600E(FDA.gov).|
|Hydroxychloroquine||Plaquenil||HCQ||Plaquenil (hydroxychloroquine sulfate) increases intralysosomal pH, resulting in inhibition of autophagic protein degradation and accumulation of autophagosomes, which potentially leads to cell death in autophagy-dependent tumor cells (NCI Drug Dictionary).|
|Panitumumab||Vectibix||ABX-EGF||EGFR Antibody 43||Vectibix (panitumumab) is a monoclonal antibody directed against EGFR, which inhibits cell proliferation and induces apoptosis (PMID: 18998757). Vectibix (panitumumab) is FDA approved for metastatic colorectal cancer patients with wild-type KRAS and NRAS (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05576896||Phase II||Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine||Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory||Recruiting||USA||0|